Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: The article by Dr Phillips and colleagues,1 which estimated the cost-effectiveness of β-blocker therapy in all patients with myocardial infarction, adds to literature documenting poor health outcomes associated with underuse of β-blockers.2 Although we agree with the conclusions that increased β-blocker use would lead to impressive gains in health, we believe that the authors neglected to consider the costs of program implementation in their analysis.
Budnitz D, Neuman WR. Underuse of β-Blockers Following Myocardial Infarction. JAMA. 2001;285(8):1013. doi:10.1001/jama.285.8.1013